Apixaban for blood clots in the portal vein after spleen removal surgery
Tests apixaban for portal vein clots found long after laparoscopic spleen removal.
Plain-language title generated from the registry record
Registry title: Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS
Key facts
- Where
- Yangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cirrhosis who had their spleen removed by keyhole surgery and later developed a blood clot in the portal vein, more than 12 months after surgery. It tests apixaban.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Cirrhosis of any cause, with an enlarged spleen and overactive spleen function. No portal vein clot before surgery. A portal vein clot developed after 12 months post-surgery.
- Earlier treatment
- Had laparoscopic spleen removal at the trial center. After surgery took apixaban 2.5 mg twice daily or aspirin 100 mg once daily for 6 months, heparin injections for 5 days, and dipyridamole 25 mg three times daily for 3 months. No clot seen on imaging in months 6 to 12.
Main reasons for not taking part
- Liver cancer or any other cancer
- Other clotting disorder not related to the liver disease
- Use of oral contraceptives, blood thinners or anti-platelet drugs
- Bleeding from portal hypertension, or Child-Pugh C liver disease
- Pregnancy or HIV infection
Read by machine on 12 November 2026.
Where in China
- Clinical Medical CollegeYangzhou, ChinaContact: Guo-Qing Jiang, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Northern Jiangsu People's Hospital
- Trial code
- NCT07461545
- Record updated
- 31 March 2026
- Original description
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.Read full original descriptionShow less
Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After Laparoscopic Splenectomy
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.
Inclusion: A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology; Splenomegaly with secondary hypersplenism; No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery; Underwent laparoscopic splenectomy at our center; Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3; subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3; Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3; Had no imaging evidence (Doppler ultrasound or CT) of portal vein thrombosis during postoperative months 6 to 12; Developed portal vein thrombosis after 12 months post-surgery; Provided informed consent to participate in the study.
Exclusion: Hepatocellular carcinoma or any other malignancy; Hypercoagulable state other than the liver disease related; Portal hypertension bleeding ; Recent peptic ulcer disease; History of Hemorrhagic stroke; Uncontrolled Hypertension; Human immunodeficiency virus (HIV) infection; DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs; Child - Pugh C; Pregnancy.